ATE279210T1 - Arzneimittel freisetzendes system enthaltend ein homeobox-peptid und ein zytotoxisches oder antineoplastisches mittel - Google Patents

Arzneimittel freisetzendes system enthaltend ein homeobox-peptid und ein zytotoxisches oder antineoplastisches mittel

Info

Publication number
ATE279210T1
ATE279210T1 AT99928071T AT99928071T ATE279210T1 AT E279210 T1 ATE279210 T1 AT E279210T1 AT 99928071 T AT99928071 T AT 99928071T AT 99928071 T AT99928071 T AT 99928071T AT E279210 T1 ATE279210 T1 AT E279210T1
Authority
AT
Austria
Prior art keywords
cytotoxic
system containing
antineoplastic agent
releasing system
drug releasing
Prior art date
Application number
AT99928071T
Other languages
English (en)
Inventor
Peter Martin Fischer
Shudong Wang
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Application granted granted Critical
Publication of ATE279210T1 publication Critical patent/ATE279210T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Refuse Collection And Transfer (AREA)
  • Threshing Machine Elements (AREA)
AT99928071T 1998-07-03 1999-06-22 Arzneimittel freisetzendes system enthaltend ein homeobox-peptid und ein zytotoxisches oder antineoplastisches mittel ATE279210T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9814527.9A GB9814527D0 (en) 1998-07-03 1998-07-03 Delivery system
PCT/GB1999/001957 WO2000001417A1 (en) 1998-07-03 1999-06-22 Delivery system

Publications (1)

Publication Number Publication Date
ATE279210T1 true ATE279210T1 (de) 2004-10-15

Family

ID=10834959

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99928071T ATE279210T1 (de) 1998-07-03 1999-06-22 Arzneimittel freisetzendes system enthaltend ein homeobox-peptid und ein zytotoxisches oder antineoplastisches mittel

Country Status (13)

Country Link
US (2) US6472507B1 (de)
EP (1) EP1093383B1 (de)
JP (1) JP2002519392A (de)
AT (1) ATE279210T1 (de)
AU (1) AU756014B2 (de)
CA (1) CA2333145C (de)
DE (1) DE69921138T2 (de)
DK (1) DK1093383T3 (de)
ES (1) ES2230860T3 (de)
GB (2) GB9814527D0 (de)
HU (1) HUP0300246A3 (de)
IL (1) IL140650A0 (de)
WO (1) WO2000001417A1 (de)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9814527D0 (en) 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system
JP2002530059A (ja) 1998-11-13 2002-09-17 サイクラセル・リミテッド 輸送ベクター
AU762006B2 (en) 1998-12-24 2003-06-19 Ucb Peptidic product, process and composition
GB9903547D0 (en) 1999-02-16 1999-04-07 Novartis Ag Organic compounds
DE19933492B4 (de) 1999-07-16 2008-01-10 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Konjugat zur Vermittlung eines zell-, kompartiment- oder membranspezifischen Transports von Wirksubstanzen, Verfahren zu dessen Herstellung und dessen Verwendung
US6864355B1 (en) * 2000-05-02 2005-03-08 Yale University Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain
US7049395B2 (en) 2000-05-02 2006-05-23 Yale University Anti-inflammatory compounds and uses thereof
GB0012528D0 (en) * 2000-05-23 2000-07-12 Univ Palackeho Triterpenoid derivatives
FR2816845B1 (fr) 2000-11-20 2006-10-20 Centre Nat Rech Scient Vecteurs de transport a travers un epithelium a jonctions serrees
JP4343534B2 (ja) * 2001-03-02 2009-10-14 ゲーペーツェー バイオテック アクチェンゲゼルシャフト ３ハイブリッド・アッセイ・システム
WO2003064614A2 (en) * 2002-01-30 2003-08-07 Yale University Transport peptides and uses therefor
EP2260874A1 (de) 2003-01-06 2010-12-15 Angiochem Inc. Aprotinin Analoga als Transportmoleküle durch die Blut-Hirn-Schranke
FR2849603B1 (fr) * 2003-01-07 2006-09-08 Centre Nat Rech Scient Composition pour le transport intracellulaire de macromolecules ou particules biologiques
US20060178297A1 (en) * 2003-01-28 2006-08-10 Troy Carol M Systems and methods for silencing expression of a gene in a cell and uses thereof
EP2662087A1 (de) * 2003-04-22 2013-11-13 Ipsen Pharma Somatostatin-vektoren
US20060229433A1 (en) * 2003-05-20 2006-10-12 Cellpep Sa Modified antiviral peptides with increased activity and cell membrane affinity
US7458683B2 (en) 2003-06-16 2008-12-02 Amo Manufacturing Usa, Llc Methods and devices for registering optical measurement datasets of an optical system
US7342114B2 (en) 2003-07-01 2008-03-11 California Pacific Medical Center Podophyllotoxin derivatives
JP5537763B2 (ja) 2003-09-05 2014-07-02 ザ ジェネラル ホスピタル コーポレイション 放出システムとしてのポリアセタール薬物抱合体
US20050148534A1 (en) * 2003-09-22 2005-07-07 Castellino Angelo J. Small molecule compositions and methods for increasing drug efficiency using compositions thereof
US8039438B2 (en) * 2003-10-20 2011-10-18 The Regents Of The University Of California Synthetic peptides that cause F-actin bundling and block actin depolymerization
US20050209147A1 (en) * 2004-01-16 2005-09-22 The Board Of Trustees Of The Leland Stanford Junior University Peptide inhibitors of RhoA signaling
EP1796708A4 (de) * 2004-09-02 2009-07-08 Cognosci Inc Verbesserte apo-e-analoge und verwendungsverfahren dafür
US8034762B2 (en) 2004-09-02 2011-10-11 Cognosci, Inc. Treatment of subarachnoid hemorrhage with Apo E analogs
US20120269886A1 (en) 2004-12-22 2012-10-25 Nitto Denko Corporation Therapeutic agent for pulmonary fibrosis
EP2730277B1 (de) 2004-12-22 2020-03-11 Nitto Denko Corporation Wirkstoffträger und Wirkstoffträgerkit zur Hemmung von Fibrose
ES2383901T5 (es) 2005-02-18 2015-02-25 Angiochem Inc. Polipéptidos de aprotinina para transportar un compuesto a través de la barrera sangre-cerebro
EP2233156B1 (de) 2005-07-15 2013-05-01 Angiochem Inc. Verwendung von Aprotinin-Polypeptiden als Träger in pharmazeutischen Konjugaten
US9572886B2 (en) 2005-12-22 2017-02-21 Nitto Denko Corporation Agent for treating myelofibrosis
BRPI0709447A2 (pt) * 2006-03-30 2011-07-12 Diatos Sa conjugado, composição farmacêutica, uso e composto
WO2007113687A2 (en) * 2006-03-30 2007-10-11 Diatos S.A. Camptothecin-cell penetrating peptide conjugates and pharmaceutical compositions containing the same
TWI407971B (zh) 2007-03-30 2013-09-11 Nitto Denko Corp Cancer cells and tumor-related fibroblasts
US9365634B2 (en) 2007-05-29 2016-06-14 Angiochem Inc. Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues
JP2010539245A (ja) 2007-09-14 2010-12-16 日東電工株式会社 薬物担体
TW200932274A (en) 2007-12-18 2009-08-01 Alcon Res Ltd Interfering RNA delivery system and uses thereof
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
US8470772B2 (en) 2008-02-27 2013-06-25 Temple University—Of the Commonwealth System of Higher Education Leptin agonist and methods of use
RU2470666C2 (ru) 2008-02-28 2012-12-27 Торэй Индастриз, Инк. Фармацевтическая композиция для трансназального введения
KR101919093B1 (ko) * 2008-05-23 2018-11-16 더 유니버시티 오브 브리티쉬 콜롬비아 리포좀 나노입자에 사용하기 위한 변형된 약물
WO2010033207A1 (en) 2008-09-19 2010-03-25 Nektar Therapeutics Polymer conjugates of therapeutic peptides
BRPI0920209A2 (pt) 2008-10-15 2015-12-22 Angiochem Inc conjugados de agonistas de glp-1 e usos dos mesmos
EP2370471B1 (de) 2008-12-05 2017-02-22 Angiochem Inc. Neurotensin konjugat und seine verwendungen
US8853353B2 (en) 2008-12-17 2014-10-07 Angiochem, Inc. Membrane type-1 matrix metalloprotein inhibitors and uses thereof
FR2941230B1 (fr) 2009-01-19 2011-03-18 Centre Nat Rech Scient Polypeptides d'adressage specifique a des cellules-cibles d'otx2
US9173891B2 (en) 2009-04-20 2015-11-03 Angiochem, Inc. Treatment of ovarian cancer using an anticancer agent conjugated to an angiopep-2 analog
US8501242B2 (en) 2009-05-29 2013-08-06 University Of Florida Research Foundation Methods and compositions for treating neoplasia
JP5932642B2 (ja) 2009-07-02 2016-06-08 アンジオケム インコーポレーテッド 多量体ペプチドコンジュゲートおよびその使用
GB201001602D0 (en) 2010-02-01 2010-03-17 Cytovation As Oligopeptidic compounds and uses therof
JP5757497B2 (ja) * 2010-10-06 2015-07-29 公立大学法人大阪府立大学 シガトキシン類ｃｔｘ１ｂおよび５４−デオキシ−ｃｔｘ１ｂを認識するモノクローナル抗体およびそれを用いるシガトキシン類検出キット
CA2846676C (en) * 2011-09-08 2020-06-23 Western University Of Health Sciences Cystine coupled targeting liposomes
CN103083239B (zh) * 2012-12-26 2015-11-25 中国人民解放军第四军医大学 一种蟾毒灵脂质体及其制备方法和应用
GB201318954D0 (en) * 2013-10-28 2013-12-11 Cupid Peptide Company Ltd Cell transport
EP4014985A1 (de) 2015-05-01 2022-06-22 Allysta Pharmaceuticals, Inc. Adiponectin-peptidomimetika zur behandlung von augenerkrankungen
GB201507722D0 (en) 2015-05-06 2015-06-17 Norwegian Univ Sci & Tech Ntnu Anti-bacterial agents and their use in therapy
CN107921143B (zh) 2015-06-15 2021-11-19 安吉奥开米公司 用于治疗软脑膜癌病的方法
US10087194B2 (en) 2015-10-27 2018-10-02 California Pacific Medical Center Podophyllotoxin derivatives and their use
JP6550538B2 (ja) 2015-10-27 2019-07-24 カリフォルニア パシフィック メディカル センター ポドフィロトキシン誘導体およびそれらの使用
WO2018085836A1 (en) 2016-11-07 2018-05-11 Colorado State University Research Foundation Anti-hiv peptides
CN110563739A (zh) * 2018-06-05 2019-12-13 薪火炙药(北京)科技有限公司 具有选择性抗肺癌作用的鬼臼毒素类化合物p-x及其制备方法和应用
GB201915454D0 (en) 2019-10-24 2019-12-11 Norwegian Univ Sci & Tech Ntnu Antibacterial bone cement and uses thereof
KR102397922B1 (ko) * 2020-02-19 2022-05-13 서울대학교 산학협력단 신규한 종양-관련 항원 단백질 olfm4 및 이의 용도
GB202006699D0 (en) 2020-05-06 2020-06-17 Therapim Pty Ltd Dosage regimen
GB202008888D0 (en) 2020-06-11 2020-07-29 Norwegian Univ Of Science And Technology (Ntnu) Peptides for sepsis treatment
MX2023007788A (es) 2021-01-24 2023-11-17 Michael David Forrest Inhibidores de la atp sintasa, usos cosmeticos y terapeuticos.

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4847240A (en) * 1978-01-16 1989-07-11 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US5043329A (en) * 1987-02-17 1991-08-27 Board Of Regents, University Of Texas System Methods and compositions employing unique mixtures of polar and neutral lipids for protecting the gastrointestinal tract
DE3836971C1 (de) * 1988-10-31 1990-05-17 Weck, Wolfgang, Dr.Med., 6990 Bad Mergentheim, De
US5888762A (en) * 1990-06-05 1999-03-30 Centre National De La Recherche Scientifique (Cnrs) Neurotropic growth factors comprising a homeobox peptide
FR2662698A1 (fr) 1990-06-05 1991-12-06 Centre Nat Rech Scient Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite.
DE69132567D1 (de) 1990-10-15 2001-05-03 Tecnogen Scpa Verfahren zur Feststellung von proteolitischen Wirkungen und/oder deren Inhibitoren
US5580563A (en) * 1992-05-01 1996-12-03 Tam; James P. Multiple antigen peptide system having adjuvant properties, vaccines prepared therefrom and methods of use thereof
US5674977A (en) 1993-02-05 1997-10-07 The Ontario Cancer Institute Branched synthetic peptide conjugate
US5807746A (en) 1994-06-13 1998-09-15 Vanderbilt University Method for importing biologically active molecules into cells
FR2739621B1 (fr) * 1995-10-05 1997-12-05 Centre Nat Rech Scient Peptides utilisables comme vecteurs pour l'adressage intracellulaire de molecules actives
US5843903A (en) * 1995-11-27 1998-12-01 The Administrators Of The Tulane Educational Fund Targeted cytotoxic anthracycline analogs
US6344436B1 (en) 1996-01-08 2002-02-05 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
AU739028B2 (en) * 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
US5929042A (en) 1997-03-03 1999-07-27 The Trustees Of Columbia University In The City Of New York Antisense compounds which prevent cell death and uses thereof
US6635623B1 (en) 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
DE69827260T2 (de) * 1997-07-24 2006-02-16 PerSeptive Biosystems, Inc., Framingham Konjugate von transportpeptiden und nukleinsäureanaloga und deren verwendung
US5823345A (en) * 1997-07-24 1998-10-20 Berry Plastics Corporation Stackable receptacle assembly for pourable products
GB9718609D0 (en) * 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
US6015787A (en) * 1997-11-04 2000-01-18 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain
GB9814527D0 (en) * 1998-07-03 1998-09-02 Cyclacel Ltd Delivery system

Also Published As

Publication number Publication date
DK1093383T3 (da) 2005-02-14
GB9814527D0 (en) 1998-09-02
HUP0300246A2 (en) 2003-05-28
DE69921138T2 (de) 2005-11-24
EP1093383B1 (de) 2004-10-13
US6992169B2 (en) 2006-01-31
GB2340121A (en) 2000-02-16
DE69921138D1 (de) 2004-11-18
CA2333145A1 (en) 2000-01-13
GB9914577D0 (en) 1999-08-25
WO2000001417A1 (en) 2000-01-13
IL140650A0 (en) 2002-02-10
EP1093383A1 (de) 2001-04-25
GB2340121B (en) 2000-09-06
US20030119735A1 (en) 2003-06-26
ES2230860T3 (es) 2005-05-01
HUP0300246A3 (en) 2005-09-28
AU756014B2 (en) 2003-01-02
AU4519899A (en) 2000-01-24
CA2333145C (en) 2008-03-25
JP2002519392A (ja) 2002-07-02
US6472507B1 (en) 2002-10-29

Similar Documents

Publication Publication Date Title
ATE279210T1 (de) Arzneimittel freisetzendes system enthaltend ein homeobox-peptid und ein zytotoxisches oder antineoplastisches mittel
EE200000380A (et) 11ß-halogeno-7(alfa)-asendatud östratrieenid, neid 11ß-halogeno-7(alfa)-asendatud östratrieene sisaldavate farmatseutiliste preparaatide valmistamise meetodid ja nende kasutamine ravimite valmistamiseks
DE69531741D1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
ATE286725T1 (de) Neue oral anzuwendende arzneizubereitungen für rivastigmine mit kontrollierter wirkstoffabgabe
HK1021539A1 (en) Androstene derivatives.
HUP0001136A2 (hu) Limfatikus tumorok kezelésére szolgáló gyógyszerkészítmények
HUP0300290A2 (hu) Érkárosító hatású kombinácíós készítmény és terápia
CA2120062A1 (en) Use of Sulodexide and of Medicines Containing It in the Treatment of Diabetic Nephropathy
ATE240303T1 (de) 1,2,4-triazol-3-thion verbindungen
TR200503846T2 (tr) Değiştirilmiş salimli ensülin sensitizörü için fterkip ve kullanımı
AR016427A1 (es) CONJUGADOS uTILES PARA EL TRATAMIENTO DE CÁNCER DE PRoSTATA, Y UNA COMPOSICIoN FARMACÉUTICA QUE LOS COMPRENDE.
GB9509888D0 (en) Terpenoidic derivatives useful as antitumour agents
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
ATE281166T1 (de) Tizoxanide und/oder nitazoxanide enthaltende pharmazeutische zubereitungen
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
GEP20032975B (en) Echinocandin Derivatives, Preparation Method and Pharmaceutical Composition
DE59510583D1 (de) Pharmazeutische zusammensetzung zur systemischen transdermalen verabreichung mit dem wirkstoff morphin-6-glucuronid
ATE313323T1 (de) Pharmazeutische zubereitungen
ATE257377T1 (de) Blister enthaltend ein transdermales therapeutisches system und eine einzeldosierte darreichungsform
EE9700021A (et) Fibriinile mõju avaldav monoklooniline antikeha kasutamiseks tromboosivastases ravis, farmatseutilised kompositsioonid ja ravimaine
CA2458872A1 (en) Human ubiquitin-conjugating enzyme

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1093383

Country of ref document: EP

REN Ceased due to non-payment of the annual fee